Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 1.00 |
| ▸ | CNR1 | P21554 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sr-144528 SCHEMBL1546003 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL14355050 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL8137029 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL8039660 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL8313006 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL19551517 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL13883212 | 0.94 | CNR2 (0.88) | CNR2CNR1 | |
| SCHEMBL13926164 | 0.94 | CNR2 (0.88) | CNR2CNR1 | |
| SCHEMBL15377558 | 0.92 | CNR2 (0.85) | CNR2CNR1 | |
| SCHEMBL8042546 | 0.92 | CNR2 (0.85) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | claimed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| US-12274727-B2 | Cannabigerol (CBG) products and methods of use | Bzelet Health Systems, Inc. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240180987-A1 | CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE | BAZELET HEALTH SYSTEMS INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11890311-B1 | Cannabigerol (CBG) products and methods of use | Bazelet Health Systems, Inc. (US) | 2024-02-06 | — | — | US | disclosed |
| US-10894069-B2 | Topical antiviral formulations and methods of using the same | MCELVANY CHRISTOPHER A (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200230187-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | MCELVANY CHRISTOPHER A (US) | 2020-07-23 | — | — | US | disclosed |
| EP-2501669-B1 | ARYLATED CAMPHENES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2018-01-24 | — | — | EP | disclosed |
| US-9365534-B2 | Arylated camphenes, processes for their preparation and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-06-14 | — | — | US | disclosed |
| US-9326927-B2 | Use of cannabinoid compounds for stimulating melanogenesis | L'OREAL (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD | 2008-03-13 | — | — | US | disclosed |
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| EP-0868420-B1 | 3-PYRAZOLECARBOXAMIDE DERIVATIVES HAVING CANNABINOID RECEPTOR AFFINITY | SANOFI SYNTHELABO (FR) | 2000-03-29 | — | — | EP | disclosed |
| EP-0885889-A2 | Process for the preparation of pyrazole-3-carboxylic acids | SANOFI (FR) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | CNR2 723/4885CNR1 580/4885 |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | CNR2 413/4885CNR1 382/4885 |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR2 1/4885CNR1 2/4885 |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | CNR2 413/4885CNR1 382/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.